

INDEX TO KEY WORDS

(Vol. 7)

A

A20 haploinsufficiency	502
abnormal scar	183
acanthosis	298
acne	226
acquired idiopathic generalized anhidrosis (AIGA)	280
acute and chronic wounds	200
adverse drug reaction	480
adverse event	398
adverse reaction	433
age-associated B cells (ABCs)	117
aging	84, 97, 152, 157, 567
allergic inflammation	509
allopurinol	494
alopecia areata (AA)	280, 467
androgenic alopecia (AGA)	147
angioedema with eosinophilia	293
angiolympoid hyperplasia with eosinophilia (ALHE)	330
animal bite	206
annular erythema	361
anti-cancer drug	398
antibiotics	238, 447
antifungal drugs	447
antigen presentation	518
antiherpesvirus agents	440
artificial intelligence (AI)	6, 18, 24, 30, 42, 49, 61
aspirin intolerance	165
atopic dermatitis (AD)	73, 298, 455
ATP	175
atrophic scar	226
autoimmune	567
autoimmune bullosa	220
autoimmune disease	35, 425, 561

B

back propagation	54
baricitinib	467
basal cell carcinoma	124
basophil	298, 509
Behcet's disease	220
bexarotene	433
biologics	425
blister	287
blood vessels	105
brentuximab vedotin	433
bruises	188
bullous pemphigoid (BP)	117, 354
burn	213
burn index (BI)	213
Buruli ulcer	238

C

cancer	336
cancer-associated fibroblasts	573
capillaroscopy	387
carbamazepine	494
cat bite	206
CD4 ⁺ T cells	567
CD81	549
cell surface molecules	544
Charcot-Leyden crystals	308
ChatGPT	61
chemokine	345, 544
chemotherapy	488
child abuse	188
chromosomal recombination	141
chronic inflammation	135
chronic lesion	298
clinical images	12
clinical information	12
clinical utility	494

Cockayne syndrome (CS)	141
COL17	147
collagen diseases.....	425
conjunctivitis	412
corium dermis.....	97
CRT2	322
cutaneous angiosarcoma.....	124
cutaneous inflammatory disorders.....	544
cutaneous ischemia-reperfusion (I/R)	
injury	175
cutaneous lupus erythematosus (CLE)	581
cutaneous neoplasm	398
cutaneous nontuberculous mycobacteriosis	238
cutaneous T-cell lymphoma.....	433
cytokine.....	345
cytomegalovirus.....	157, 561
cytotoxic CD4 ⁺ T cell	
(CD4 ⁺ CTL)	129, 157, 561

D

data-driven research.....	66
debridement	193, 213
deep dissecting hematoma (DDH)	232, 502
deep learning	30, 54
delgocitinib.....	455
dermal dendritic cell	518
dermatomyositis.....	581
dermatoporosis	232
dermis	91, 525
dermoscopic images	12
dermoscopy.....	18
difamilast	455
digital device	49
disaster	256
disaster area	252
disaster medicine	245
disseminated superficial	
actinic porokeratosis	141
DNA damage response (DDR)	84
dog bite	206
drug eruption	336
drug-induced hypersensitivity syndrome	
(DIHS)	280

drug-induced hypersensitivity syndrome/	
drug reaction with eosinophilia and	
systemic symptoms (DIHS/DRESS)	303

E

edematous erythema.....	412
electrodermal activity (EDA)	49
Eomes	525
eosinophil.....	287, 293, 298, 303, 308,
316, 345, 354, 361, 366	
eosinophil extracellular trap.....	308, 345
eosinophil granule protein	354
eosinophilic granulomatosis with polyangiitis	
(EGPA)	308, 361, 581
eosinophilic spongiosis	379
eotaxin-3	322
epidermis	79, 91, 525
epidermolysis bullosa (EB)	79
epigenetic	152
erythema	287
erythema multiforme (EM)	303
ethical, legal, and social issues (ELSI)	1, 49
exhausted T cell (Tex)	538

F

fasciitis.....	316
fibroblast	97
fibrogenesis.....	316
fibrosis.....	129, 573
flame figure	287
function	345

G

gastrointestinal endoscopy	42
generalized pustular psoriasis (GPP)	165
generative AI	61
glucocorticoids (GC)	418
glycopyrronium tosylate	462
GRADE approach	274

H

hair follicle stem cells (HFSCs)	147
hair greying.....	147

HBV-DNA.....	488
hemidesmosome	79
hepatitis B virus	488
herpesvirus helicase-primase complex	440
histopathology.....	379
human immunodeficiency virus (HIV)	322
human leukocyte antigen (HLA)	494
human polyomavirus 6 (HPyV6)	322
hydroxychloroquine (HCQ)	418, 425
hypereosinophilic syndrome (HES)	339, 373
hyperpigmentation	361
hypertrophic scar	183, 226

I

IFN- γ	467
IL-5	373
IL-17	406
IL-23	406
IL-36	406
image diagnosis.....	18
immune aging	129
immune checkpoint inhibitor (ICI)	393, 538
immune checkpoint molecule	538
immune suppression	549
immune-related adverse event (irAE)	393
immunosuppressant	418
immunosuppressive therapy	488
indomethacin.....	322
inflammaging.....	112
injection site-reaction	412
innate immunity	531
innate lymphoid cells (ILC)	531
interleukin (IL)-4.....	509
interstitial pneumonia.....	452
intravenous immunoglobulin (IVIG)	425
itch	366

J

JAK inhibitors.....	467
---------------------	-----

K

Kampo medicine	452
keloid.....	183

keratinocytes.....	171
Kimura disease (KD)	330

L

Langerhans cell (LC)	518
large language model (LLM)	61
lichen planus	220
lichen sclerosus et atrophicus.....	220
linear IgA bullous dermatosis (LABD)	165
livedoid vasculopathy	581
liver dysfunction.....	452
lymphatic.....	105
lymphoma.....	336

M

machine learning (ML)	61, 66
maculopapular exanthema (MPE)	303
maintenance therapy	226
malignant melanoma	124
mamushi bite.....	206
mature regulatory DC (mregDC)	518
medical artificial intelligence	1
medical service	6
meflin	573
MEK inhibitor	473
melanocyte	556
melanocyte stem cells (McSCs)	147
melanoma.....	18, 393
mesenteric phleboscrosis.....	452
meta-analysis	274
microclimate.....	260
mogamulizumab.....	433
molecular targeted therapy	73
multimodal learning	12

N

nailfold capillary changes.....	35
National Skin Disease Database (NSDD)	54
natural killer (NK) cells	525
negative pressure wound therapy (NPWT)	200
neurofibromatosis type 1 (NF1)	473
neutrophil extracellular traps.....	502
no-fault compensation	480

nociceptor.....	556
nucleos (t) ide analogues.....	440

O

online management.....	252
oxidative stress.....	175
oxybutynin hydrochloride.....	462

P

papuloerythroderma of Ofuji	336
PDE4 inhibitor	509
pemphigus.....	117
pemphigus herpetiformis	73
pemphigus vulgaris.....	280
Pharmaceuticals and Medical Devices Agency (PMDA)	480
Piezo1.....	91
plasmacytoid DC (pDC)	518
polarity	79
pressure redistribution.....	260
pressure ulcer	252, 256, 260
primary focal hyperhidrosis.....	165
propantheline bromide.....	462
pruritus.....	366, 509
pseudoaldosteronism	452
pseudonymization	1
psoriasis	24, 135, 406, 455
psoriasis area and severity index (PASI) score	24
psoriatic arthritis.....	35
psoriatic disease	135
psychiatry.....	49
puffy finger.....	35
purpura.....	287

Q

qualitative systematic review.....	274
------------------------------------	-----

R

RB.....	84
reactivation.....	488
recombinant zoster vaccine.....	440
regulatory T cell (Treg)	117, 549

relief system.....	480
resident memory T cells (T _{RM})	544
ritlecitinib	467
rituximab	280
Rosai-Dorfman disease.....	73

S

salazosulfapyridine	494
scar	226
scarless wound healing	573
scleroderma pattern	387
scleroderma-like pattern	387
secondary use of medical data	1
self-supervised learning	54
selumetinib sulfate	473
senescence	84, 135
senescence-associated secretory phenotype (SASP)	84, 112
senescence-associated (SA) T cell	117
senescent cell	157, 561
senile lentigo	556
sensory nerve	556
sentinel injury	188
severe cutaneous adverse drug reactions (SCARs)	30
sex transmitted disease	220
side effect.....	462
SimCLR.....	54
single cell analysis.....	97
skin cancer	18, 124, 393
skin disease	12
skin grafting and reconstruction.....	200
skin lesion of child abuse	188
skin neglected tropical disease (NTDs)	238
skin tear.....	193
skin-aging	105
sofpironium bromide.....	462
software as a medical device (SaMD)	6
solar lentigo.....	556
squamous cell carcinoma	124
start up	6
stem cell	91, 152, 171
Stevens-Johnson syndrome (SJS)	30

stiffness	91
stratification	66
subepidermal blister	379
supervised learning	66
support surface	260
supporting care	256
surgical debridement	200
surgical treatment	238
suture technique	193
systemic lupus erythematosus (SLE)	581
systemic sclerosis (SSc)	35, 129, 387

T

T cell	112
T-bet	525
tapinarof	455
TEN-4-FACESp	188
Th2	330
ThA cells	567
thymine dimer	141
thymoma-associated multiorgan autoimmunity	502
TIME concept	266
tissue resident	531
topical formulation of mTOR inhibitor	473
topical medicines	266
total burn surface area	213
toxic epidermal necrolysis (TEN)	30
transcriptional factors	544
transgressions	502
trauma	193
tuberous sclerosis complex (TSC)	73, 473

tumor necrosis factor (TNF)	406
type 2 inflammation	366, 373
type XVII collagen	79
tyrosine kinase inhibitor	398

U

ultraviolet-B (UVB)	549
unsupervised learning	66
urticaria	293

V

vasculitis	308, 379
vasculopathy	379
VEXAS syndrome	165
virome	157, 561
visualization	105

W

Wells syndrome (WS)	361
wound dressings	266
wound healing	152, 171, 175, 266, 549, 573
wound management	200, 245
wound ostomy and continence nurse (WOCN)	256

X

xeroderma pigmentosum (XP)	141
----------------------------------	-----

Z

zinc	175
zoster vaccine live	440